{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:42:23Z","timestamp":1793817743421,"version":"4.6.1"},"reference-count":335,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.drup.2026.101452","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:29:20Z","timestamp":1784388560000},"page":"101452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies"],"prefix":"10.1016","volume":"89","author":[{"given":"Sha","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101452_bib1","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib4","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib5","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101452_bib6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib7","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","article-title":"Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia","volume":"59","author":"Albinger","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.drup.2026.101452_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101452_bib10","doi-asserted-by":"crossref","first-page":"0023","DOI":"10.34133\/cancomm.0023","article-title":"Harnessing the power of CAR-NK cells for solid tumors: challenges, innovations, and future frontiers in immunotherapy","volume":"46","author":"An","year":"2026","journal-title":"Cancer Commun."},{"key":"10.1016\/j.drup.2026.101452_bib11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib12","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1084\/jem.167.2.452","article-title":"Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells","volume":"167","author":"Aneg\u00f3n","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101452_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101452_bib15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s43018-024-00798-x","article-title":"\u03b3\u03b4 T cells as critical anti-tumor immune effectors","volume":"5","author":"Arias-Badia","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib17","article-title":"Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer","volume":"6","author":"Aznar","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.drup.2026.101452_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib19","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib21","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.cell.2026.06.002","article-title":"AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy","volume":"189","author":"Baker","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","article-title":"CAR-engineered cell therapies: current understandings and future perspectives","volume":"7","author":"Bayat","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.drup.2026.101452_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020459","article-title":"Development of a TGF\u03b2-IL-2\/15 switch receptor for use in adoptive cell therapy","volume":"11","author":"Beck","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101452_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib25","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.immunol.17.1.189","article-title":"Natural killer cells in antiviral defense: function and regulation by innate cytokines","volume":"17","author":"Biron","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib28","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1016\/j.cell.2026.04.037","article-title":"Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis","volume":"189","author":"Bjelajac","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib30","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ymthe.2026.03.007","article-title":"Efficient multiplex non-viral engineering and expansion of polyclonal \u03b3\u03b4 CAR-T cells for immunotherapy","volume":"34","author":"Bridge","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.03.007","article-title":"Efficient multiplex non-viral engineering and expansion of polyclonal \u03b3\u03b4 CAR-T cells for immunotherapy","author":"Bridge","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib32","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1084\/jem.188.8.1521","article-title":"CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution","volume":"188","author":"Brossay","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101452_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101452_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40164-025-00625-8","article-title":"Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer","volume":"14","author":"Cai","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2025.02.002","article-title":"Reshaping the immune microenvironment and reversing immunosenescence by natural products: prospects for immunotherapy in gastric cancer","volume":"110","author":"Cao","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101452_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41590-025-02391-5","article-title":"BACH2 regulates T cell lineage state to enhance CAR T cell function","volume":"27","author":"Chang","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib39","first-page":"379","article-title":"Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment","volume":"42","author":"Chang","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.drup.2026.101452_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2025.01.012","article-title":"Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101452_bib41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101452_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.193048","article-title":"Enhancing the potency of CAR-T cells against solid tumors through transcription factor engineering","volume":"10","author":"Chen","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101452_bib45","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","article-title":"CRISPR-Cas9 applications in T cells and adoptive T cell therapies","volume":"29","author":"Chen","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.drup.2026.101452_bib47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12964-024-01894-2","article-title":"Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape","volume":"22","author":"Chen","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.drup.2026.101452_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-026-01792-9","article-title":"Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies","volume":"19","author":"Chen","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303215","article-title":"Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies","volume":"10","author":"Chen","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101452_bib50","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2026.101452_bib51","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib54","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib55","article-title":"Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy","volume":"11","author":"Chung","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib56","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-26-1515","article-title":"Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma","author":"Clubb","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib57","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s43018-023-00604-0","article-title":"Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy","volume":"4","author":"Coorens","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib58","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib59","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib60","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101452_bib62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41551-025-01610-6","article-title":"Ablation of prostaglandin E(2) signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours","volume":"10","author":"D\u00f6rr","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drup.2026.101452_bib64","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001334","article-title":"Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting","volume":"9","author":"Eitler","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib68","doi-asserted-by":"crossref","first-page":"eadn9857","DOI":"10.1126\/sciadv.adn9857","article-title":"Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer","volume":"10","author":"Erler","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101452_bib69","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101452_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101200","article-title":"YTHDF2-mediated m(6)A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI","volume":"79","author":"Fan","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101452_bib71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01450-4","article-title":"Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses","volume":"10","author":"Fan","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drup.2026.101452_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102515","article-title":"Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform","volume":"20","author":"Fang","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.drup.2026.101452_bib73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.2371564","article-title":"Structural mutations of the T cell receptor zeta chain and its role in T cell activation","volume":"249","author":"Frank","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101452_bib74","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2519819123","article-title":"Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma","volume":"123","author":"Fu","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101452_bib75","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib76","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1038\/s41467-025-61348-2","article-title":"Targeting CD37 promotes macrophage-dependent phagocytosis of multiple cancer cell types and facilitates tumor clearance in mice","volume":"16","author":"Gao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-026-00899-y","article-title":"vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"Biomark. Res."},{"key":"10.1016\/j.drup.2026.101452_bib78","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib80","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2026.03.047","article-title":"Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse","volume":"189","author":"Gattinoni","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib81","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib84","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib85","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41388-025-03332-0","article-title":"Human CSPG4-targeting CAR-macrophages inhibit melanoma growth","volume":"44","author":"Greiner","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101452_bib86","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101452_bib87","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib88","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","volume":"17","author":"Gu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib89","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib90","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101452_bib91","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202521507","article-title":"Cationic mRNA lipid nanoparticles for ex vivo nanoCAR-T cell engineering","volume":"13","author":"Harinck","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101452_bib93","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib94","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib95","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib96","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib97","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib99","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101452_bib100","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.4049\/jimmunol.0904084","article-title":"Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses","volume":"184","author":"Hoelzinger","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-70867-5","article-title":"Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs","volume":"17","author":"Hou","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib102","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117753","article-title":"Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy","volume":"181","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101452_bib104","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1038\/s41467-021-26614-z","article-title":"Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface","volume":"12","author":"Hunter","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101452_bib106","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib108","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1021\/acs.jmedchem.9b00506","article-title":"Discovery of a potent and selective CCR4 antagonist that inhibits T(reg) trafficking into the tumor microenvironment","volume":"62","author":"Jackson","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101452_bib109","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","article-title":"An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma","volume":"6","author":"Jing","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib111","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib112","doi-asserted-by":"crossref","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2026.101452_bib113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101452_bib114","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib115","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41568-025-00883-y","article-title":"Epigenetic regulation of T cell exhaustion in cancer","volume":"26","author":"Kang","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib117","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib118","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib119","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib120","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2025.03.017","article-title":"Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity","volume":"188","author":"Kondo","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib121","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib122","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bjh.18797","article-title":"Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL","volume":"202","author":"Lamure","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2026.101452_bib124","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib125","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101452_bib126","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib127","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41467-023-42619-2","article-title":"Unlocking the potential of allogeneic V\u03b42 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR\/IL-15 engineering","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib129","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib131","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib132","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","volume":"34","author":"Lemgart","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib133","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1016\/j.ymthe.2025.05.026","article-title":"Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8(+) T cell activation in patients with advanced colorectal cancer","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib134","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib135","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msab335","article-title":"Evolution under spatially heterogeneous selection in solid tumors","volume":"39","author":"Li","year":"2022","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.drup.2026.101452_bib137","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib138","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib139","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41416-025-03015-3","article-title":"Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer","volume":"132","author":"Li","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123976","article-title":"Self-assembled microparticle hydrogel scaffolds to construct artificial tertiary lymphoids for enhanced CAR-T cell therapy against solid tumors","volume":"329","author":"Li","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.drup.2026.101452_bib142","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib143","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-025-68112-6","article-title":"Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T cells for recurrent high-grade glioma: preclinical characterization and phase I trial","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib144","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib145","article-title":"Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.drup.2026.101452_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01629-3","article-title":"Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy","author":"Li","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drup.2026.101452_bib148","article-title":"From bench to body: in vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2026.101452_bib149","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib150","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib151","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy-safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drup.2026.101452_bib152","article-title":"Distinct effector functions and synergy of CAR mRNA-engineered T cells and macrophages in the clearance of CD19(+) leukemia cells","author":"Liao","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.drup.2026.101452_bib153","first-page":"529","article-title":"Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails","volume":"52","author":"Liu","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.drup.2026.101452_bib154","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101452_bib156","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib157","doi-asserted-by":"crossref","first-page":"eadx8134","DOI":"10.1126\/sciadv.adx8134","article-title":"Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy","volume":"11","author":"Liu","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101452_bib158","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.14336\/AD.2022.0415","article-title":"A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20(+) lymphoma cells","volume":"13","author":"Liu","year":"2022","journal-title":"Aging Dis."},{"key":"10.1016\/j.drup.2026.101452_bib159","article-title":"CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist","volume":"7","author":"Liu","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2026.101452_bib160","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib161","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib162","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib163","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib164","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101452_bib165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41590-024-01746-8","article-title":"Targeting JMJD1C to selectively disrupt tumor T(reg) cell fitness enhances antitumor immunity","volume":"25","author":"Long","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib166","article-title":"CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines","volume":"6","author":"Look","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2026.101452_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drup.2026.101452_bib168","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cmet.2022.08.007","article-title":"ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes","volume":"34","author":"Lu","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.drup.2026.101452_bib169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/2643-3230.BCD-23-0240","article-title":"Advancing CAR T-cell therapies with artificial intelligence: opportunities and challenges","volume":"6","author":"Luciani","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib171","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-024-00546-y","article-title":"Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma","volume":"13","author":"Luo","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib172","article-title":"Chimeric antigen receptor-macrophage therapy enters the clinic: the first-in-human trial for HER2(+) solid tumors","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.drup.2026.101452_bib173","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013425","article-title":"TIPE2 deficiency enhances macrophage phagocytosis of tumor cells","volume":"13","author":"Ma","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib174","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib175","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib176","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-024-00553-z","article-title":"Efficacy of NKG2D CAR-T cells with IL-15\/IL-15R\u03b1 signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder","volume":"13","author":"Mai","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib177","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib178","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib179","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib180","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib181","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib182","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ccell.2025.12.021","article-title":"Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth","volume":"44","author":"Mateus-Tique","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib183","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib184","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","article-title":"Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells","volume":"31","author":"Maulana","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101452_bib185","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib187","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.4049\/jimmunol.167.6.3114","article-title":"Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells","volume":"167","author":"Metelitsa","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib188","doi-asserted-by":"crossref","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2026.101452_bib189","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310221120","article-title":"Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing","volume":"120","author":"Mishra","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101452_bib190","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib191","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib192","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.drup.2026.101452_bib193","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101452_bib194","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib195","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib196","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reth.2023.05.006","article-title":"An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood","volume":"24","author":"Nakazawa","year":"2023","journal-title":"Regen. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib197","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003237","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib198","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib199","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014592","article-title":"CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors","volume":"14","author":"Nardo","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib200","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","article-title":"Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies","volume":"44","author":"Nasir","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib201","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies","author":"Neelapu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib202","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib203","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib204","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","article-title":"Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming","volume":"37","author":"Niu","year":"2025","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101452_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: Mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101452_bib206","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc","volume":"7","author":"O'Neal","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101452_bib207","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.drup.2026.101452_bib208","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib209","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib210","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101452_bib211","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cytogfr.2014.11.003","article-title":"NK cells and interferons","volume":"26","author":"Paolini","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drup.2026.101452_bib212","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.drup.2026.101452_bib213","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1507","article-title":"Optimisation of a primary human CAR-NK cell manufacturing pipeline","volume":"13","author":"Pfefferle","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib215","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","article-title":"Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia","volume":"43","author":"Pham-Danis","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib216","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib217","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41586-024-08366-0","article-title":"Engineered receptors for soluble cellular communication and disease sensing","volume":"638","author":"Piraner","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib218","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib219","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1038\/s41467-024-54355-2","article-title":"C\/EBP\u03b2-dependent autophagy inhibition hinders NK cell function in cancer","volume":"15","author":"Portale","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib220","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-026-01280-8","article-title":"Progress in the development of cytokine armoured CAR T cells","author":"Prasad","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib221","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib222","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib223","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/s41467-022-33793-w","article-title":"Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis","volume":"13","author":"Qin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101149","article-title":"RGS5(+) lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism","volume":"77","author":"Qiu","year":"2024","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101452_bib225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2026.101452_bib226","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41375-024-02449-7","article-title":"The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients","volume":"39","author":"Qiu","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101452_bib227","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","article-title":"CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells","volume":"643","author":"Rafei","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib228","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib229","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149712","article-title":"Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis","volume":"138","author":"Ramos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib230","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","article-title":"Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma","volume":"40","author":"Ravi","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib231","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib232","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib233","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.2025029302","article-title":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia","volume":"147","author":"Ren","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib234","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib235","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib236","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102618","article-title":"Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing","volume":"36","author":"Roman Azcona","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.drup.2026.101452_bib238","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib239","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib240","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib241","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib242","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib243","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib244","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101452_bib245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0115665232357078250331180413","article-title":"CRISPR\/Cas9 technology for modifying immune checkpoint in CAR-T cell therapy for hematopoietic malignancies","volume":"26","author":"Shams","year":"2026","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.drup.2026.101452_bib246","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70279","article-title":"T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: a first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer","volume":"132","author":"Shan","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib247","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-026-03689-4","article-title":"Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia","volume":"45","author":"Shen","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib248","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101452_bib249","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007329","article-title":"Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy","volume":"12","author":"Shishido","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib250","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.drup.2026.101452_bib251","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.2024026216","article-title":"Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib252","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo","volume":"14","author":"Silvestre","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib254","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-23-2581","article-title":"RAS\/RAF comutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fimmu.2015.00255","article-title":"Regulation of NKT cell localization in homeostasis and infection","volume":"6","author":"Slauenwhite","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib256","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib257","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101452_bib258","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib259","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41416-025-02977-8","article-title":"CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma","volume":"132","author":"Strassheimer","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib260","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","article-title":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","volume":"12","author":"Strati","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.drup.2026.101452_bib261","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib262","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib263","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","article-title":"Macrophages: targets for next-generation cancer immunotherapy","volume":"44","author":"Sun","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib264","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/febs.17326","article-title":"Depletion of Tregs from CD4(+) CAR-T cells enhances the tumoricidal effect of CD8(+) CAR-T cells in anti-CD19 CAR-T therapy","volume":"292","author":"Sun","year":"2025","journal-title":"Febs J."},{"key":"10.1016\/j.drup.2026.101452_bib265","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib266","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02978-3","article-title":"Unraveling cellular and molecular mechanisms of relapse in CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia","author":"Tan","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2026.101452_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218450","article-title":"Targeting the aHSC-PGE(2)-NK cell axis overcomes immunosuppression and inhibits liver metastasis in fibrotic liver","volume":"652","author":"Tang","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101452_bib268","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101452_bib269","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib270","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","volume":"31","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101452_bib271","article-title":"Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15","volume":"13","author":"Tian","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib272","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/bloodadvances.2025017573","article-title":"CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo","volume":"10","author":"Tilsed","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101452_bib273","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101452_bib274","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib275","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2026.2626181","article-title":"DRP1 depletion protects NK cells from hypoxia-induced dysfunction","volume":"31","author":"Verhezen","year":"2026","journal-title":"Redox Rep."},{"key":"10.1016\/j.drup.2026.101452_bib276","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1158\/0008-5472.CAN-18-1119","article-title":"Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer","volume":"78","author":"Villarreal","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib277","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib278","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib279","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101452_bib280","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00262-025-04196-9","article-title":"NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.drup.2026.101452_bib281","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-015114","article-title":"Clinical outcomes and spatial transcriptomic profiles of CD19\/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"14","author":"Wang","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib282","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib283","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib284","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cac2.70053","article-title":"Harnessing chimeric antigen receptor macrophages against solid tumors","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.drup.2026.101452_bib285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibtech.2025.12.001","article-title":"CRISPR\/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming","author":"Wang","year":"2026","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib286","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ijc.70117","article-title":"Antigen escape in CAR-T therapy: a tumor microenvironment perspective from hematological to solid tumors","volume":"158","author":"Wang","year":"2026","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib287","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drup.2026.101452_bib288","article-title":"mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies","volume":"33","author":"Wang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2026.101452_bib289","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semcancer.2023.04.009","article-title":"Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology","volume":"93","author":"Wang","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101452_bib290","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0140-6736(23)01699-9","article-title":"Towards functional precision oncology with human organoids","volume":"402","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101452_bib291","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101452_bib292","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-25-1201","article-title":"CAR-macrophage cell therapy: a new era of hope for pancreatic cancer","volume":"31","author":"Wei","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib293","article-title":"Industrializing CAR-T cell therapy: impact of automation on cost and space efficiency of manufacturing facilities","volume":"13","author":"Weltin","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.drup.2026.101452_bib294","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable smart CAR-T design: a new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","volume":"640","author":"Wen","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101452_bib295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101452_bib296","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib297","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cytogfr.2023.08.010","article-title":"Exosome-mediated metabolic reprogramming: Implications in esophageal carcinoma progression and tumor microenvironment remodeling","volume":"73","author":"Xi","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drup.2026.101452_bib298","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drup.2026.101452_bib299","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib300","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101452_bib301","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib302","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2025.11.009","article-title":"Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells","volume":"44","author":"Yagel","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101452_bib303","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib304","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral sleeping beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101452_bib305","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101452_bib306","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-24-0352","article-title":"Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy","volume":"30","author":"Yang","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib307","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drup.2026.101452_bib308","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-025-03351-5","article-title":"A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells","volume":"44","author":"Yi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib309","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","article-title":"CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit","volume":"6","author":"Yi","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib310","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.drup.2026.101452_bib311","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101452_bib312","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","article-title":"Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape","volume":"8","author":"Zhai","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib313","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.ymthe.2023.04.008","article-title":"Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib314","article-title":"Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors","volume":"7","author":"Zhang","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2026.101452_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189520","article-title":"Targeting the tumor immune microenvironment in chordoma: From mechanistic insights to therapeutic breakthroughs","volume":"1881","author":"Zhang","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib316","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101452_bib317","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","article-title":"Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101452_bib318","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101360","article-title":"Tumor immune organoids in immunotherapy resistance and drug screening","volume":"85","author":"Zhang","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2026.101452_bib319","first-page":"1","article-title":"MAL2 drives hepatocellular carcinoma progression by recruiting regulatory T cells via CCL22 and inducing the immunosuppressive microenvironment","volume":"58","author":"Zhang","year":"2026","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.drup.2026.101452_bib320","doi-asserted-by":"crossref","first-page":"138","DOI":"10.21147\/j.issn.1000-9604.2024.02.04","article-title":"Hypoxic tumor microenvironment: destroyer of natural killer cell function","volume":"36","author":"Zhang","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101224","article-title":"DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal \u03b2-oxidation in hepatocellular carcinoma","volume":"81","author":"Zhang","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2026.101452_bib322","article-title":"Immunotherapy resistance in triple-negative breast cancer: mechanisms and emerging therapeutic strategies","author":"Zhao","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101452_bib323","article-title":"Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7\/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis","volume":"11","author":"Zhao","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib324","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02674-x","article-title":"Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications","volume":"25","author":"Zhao","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101452_bib326","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib327","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1186\/s12885-023-11536-4","article-title":"Ray of dawn: anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib328","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s42003-025-09390-0","article-title":"Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-\u03b3\u03b4 T evaluation","volume":"8","author":"Zhu","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.drup.2026.101452_bib329","article-title":"Rational design and organoid-based evaluation of a cocktail CAR-\u03b3\u03b4 T cell therapy for heterogeneous glioblastoma","volume":"12","author":"Zhu","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101452_bib330","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12916-025-03968-5","article-title":"Elevated CD10(-) neutrophils correlate with non-response and poor prognosis of CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"23","author":"Zhu","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.drup.2026.101452_bib331","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101452_bib332","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013211","article-title":"MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model","volume":"14","author":"Zhu","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101452_bib333","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41590-023-01685-w","article-title":"FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells","volume":"25","author":"Zhu","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2026.101452_bib334","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202407425","article-title":"Photo-metallo-immunotherapy: fabricating chromium-based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors","volume":"37","author":"Zou","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2026.101452_bib335","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ccell.2025.11.007","article-title":"IL-36\u03b3 armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity","volume":"44","author":"Zuo","year":"2026","journal-title":"Cancer Cell"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:06:22Z","timestamp":1789787182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":335,"alternative-id":["S1368764626001032"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101452","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101452"}}